Gujarat Inject profit up 78% to ₹1.81 cr; sales ₹36.32 cr

FY26 results: profit and revenue move higher

Gujarat Inject (Kerala) Ltd reported audited standalone financial results for the year ended March 31, 2026, showing a strong year-on-year improvement in profitability and revenue. Net profit for FY26 came in at ₹1.81 crore, up 77.45% from ₹1.02 crore in FY25. Revenue from operations rose to ₹36.32 crore in FY26 compared with ₹19.05 crore a year earlier, reflecting a 90.66% increase.

The company’s full-year total income was reported at ₹36.52 crore, up from ₹19.23 crore in the corresponding prior period. The FY26 numbers indicate that the earnings growth was supported by higher revenue, although expenses also increased materially during the year.

March 2026 quarter: net profit jumps over 2,200%

The quarter ended March 31, 2026, stood out for the scale of improvement versus the same quarter last year. Gujarat Inject (Kerala) reported net profit of ₹1.64 crore in the March 2026 quarter, compared with ₹0.07 crore in the March 2025 quarter, a jump of 2,242.86%.

Sales for the March 2026 quarter rose to ₹30.70 crore from ₹4.24 crore in the March 2025 quarter, translating into growth of 624.06%. In the audited standalone disclosure, revenue from operations for the quarter was reported at ₹30.70 crore and total income was also ₹30.70 crore.

Expense trend and tax line items

While revenue increased, costs also moved higher. Total expenses for FY26 were reported at ₹34.01 crore, compared with ₹17.97 crore in FY25. For the March 2026 quarter, total expenses were stated at ₹28.43 crore.

Profit before exceptional items and tax for FY26 was reported at ₹2.50 crore, up from ₹1.25 crore in FY25. The tax expense for FY26 was reported at ₹0.69 crore.

Nine-month and Q3 context: growth with uneven profitability

The company’s reported performance across interim periods shows that revenue growth did not translate into consistent profit expansion in every quarter. For the third quarter ended December 31, 2025 (Q3FY26), revenue from operations was reported at ₹1.63 crore, up from ₹0.14 crore in Q3FY25.

However, Q3FY26 net profit was reported at ₹0.04 crore, lower than ₹0.07 crore in Q3FY25. For the nine months ended December 31, 2025, revenue from operations was stated at ₹5.02 crore versus ₹0.20 crore in the comparable period, while net profit was ₹0.94 crore compared with ₹1.02 crore.

These interim figures, followed by a sharp improvement in the March 2026 quarter, highlight that FY26 performance was uneven across the year even as the full-year result improved.

Board changes: Managing Director resigns, new Chairman appointed

Alongside the financial update, Gujarat Inject Kerala Limited disclosed Board-level changes. The Board of Directors, at its meeting on May 16, 2026, approved the resignation of Mr. Murli Shivshankaran Nair as Managing Director and Chairman with immediate effect, citing personal commitments.

At the same meeting, Mr. Deepak Diwan Bachwani was appointed as Whole Time Director and designated Chairman, effective May 16, 2026, subject to member approval.

Separately, the company also reported that Independent Director Mrs. Reena Mahatma resigned with effect from December 9, 2025.

Stock snapshots reported across platforms

Market data points cited alongside the company profile varied by date and source. One snapshot showed a price of ₹106.90 with a decline of ₹2.15 (down 1.97%) as of May 13, 2026. Another stated a current market price of ₹95.50 with a market capitalisation of about ₹140 crore. A further data point listed market capitalisation at ₹149.57 crore as of May 22, 2026.

A separate price update stated the share closed at ₹102.1, with an intraday high of ₹103.5 and low of ₹102.1. These figures reflect reporting at different times and should be read as point-in-time references rather than a single consolidated quote.

Company footprint and classification

Gujarat Inject (Kerala) is shown under the Healthcare sector and Labs and Life Sciences Services industry in one profile, and described as operating in the pharmaceuticals segment in another. The company location is referenced as Palakkad, Kerala, while the registered office address is listed in Vadodara, Gujarat.

The BSE scrip code is cited as 524238. One profile also mentioned an NSE symbol, though the same section did not provide an NSE series.

Key figures at a glance (all amounts in ₹ crore)

What investors typically track from here

With audited FY26 results and a major March-quarter jump now on record, the next focus areas for investors are usually consistency of quarterly execution and clarity on leadership transition. The company has already disclosed the Managing Director and Chairman resignation and the appointment of a new Chairman, effective May 16, 2026, subject to member approval.

Operationally, the year showed both sharp revenue expansion and higher expenses. Future quarterly disclosures will help investors assess whether the cost structure stabilises relative to revenue, especially after the large March-quarter move.

Conclusion

Gujarat Inject (Kerala) closed FY26 with net profit of ₹1.81 crore on revenue of ₹36.32 crore, supported by a sharp rise in March-quarter sales and profit compared with the year-ago period. Alongside the numbers, the company disclosed key Board changes effective May 16, 2026, with member approval pending for the Chairman designation.